Epithelial ovarian cancer remains a major women′ s health problem due to its high
lethality. Despite great efforts to develop effective prevention and early detection strategies …

BACKGROUND: Despite improvements in the treatment of ovarian cancer, most patients
develop recurrent disease within 3 years of diagnosis. There is no agreed second-line …

Background Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer.
Pazopanib is an anti-angiogenic drug active in ovarian cancer. We assessed the effect of …

Ovarian cancer is a deadly malignancy with a growing therapeutic armamentarium, though
achieving sustained benefit in the clinic remains largely elusive. Through biomarker and …

Despite survival gains achieved nearly two decades ago with combination platinum-and
taxane-based intravenous chemotherapy, overall survival curves have remained relatively …

At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup
(GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative …

Opinion statement In ovarian cancer (OC), the best established anti-angiogenic drug,
bevacizumab, has demonstrated only modest prolonged progression free survival (PFS) and …

du Bois A, Pfisterer J. Future options for first‐line therapy of advanced ovarian cancer. Int J
Gynecol Cancer 2005; 15 (Suppl. 1): 42–50. The current standard of treatment for patients …

Ovarian cancer is the most common cause of mortality of tumors from gynecologic origin and
is often diagnosed after patients have already progressed to advanced disease stage. The …

Although the results of treatment of ovarian cancer have improved over the past 20 years
with the introduction of platinum and more recently taxoid-based chemotherapy, the majority …